NCI issues omics checklist for tests

Area of Science:

• Oncology
• Bioinformatics
• Translational Medicine

Background:

• The National Cancer Institute (NCI) has introduced a comprehensive 30-item checklist.
• This checklist evaluates the clinical trial readiness of complex omics-based tests.
• These tests integrate multiple molecular data types for predictive modeling.

Discussion:

• The checklist addresses tests combining genomic, proteomic, metabolomic, transcriptomic, and epigenomic data.
• It focuses on the predictive mathematical models derived from these multi-omics assays.
• Ensuring test validity is crucial for guiding therapeutic choices in clinical trials.

Key Insights:

• A standardized 30-item checklist is now available for omics test evaluation.
• The NCI mandates adherence to all criteria for test approval in clinical trials.
• This initiative aims to enhance the reliability of omics-based companion diagnostics.

Outlook:

• This standardization is expected to accelerate the adoption of validated omics tests in cancer research.
• It will improve the precision of therapeutic selection for patients in clinical trials.
• Future iterations may expand criteria to include novel omics technologies and data integration methods.